Under the partnership, both companies will collaborate at BioCentriq's good manufacturing practice (GMP) facilities in New Jersey to produce Tevogen's proprietary COVID-19-targeted T cells. The goal is to achieve large-scale manufacturing of clinical-grade, allogeneic T-cell therapy.

The U.S. Food and Drug Administration (FDA) is currently reviewing Tevogen's investigational new drug (IND) application for the antigen-specific T-cell therapy. In upcoming trials, Tevogen will study its COVID-19-specific CD8+ T cells, TVGN-489, for the drug's safety and ability to recognize and eliminate COVID-19-infected cells.

Financial details of the partnership were not disclosed.

Capricor begins phase II trial of COVID-19 cell therapy
Capricor Therapeutics has begun a phase II trial of its CAP-1002 cell therapy for patients with severe COVID-19 disease.

Novartis secures exclusive rights to potential COVID-19 cell therapy
Novartis has entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize, and manufacture remestemcel-L...

Novocellbio's COVID-19 cell therapy shows promising results
Novocellbio has confirmed that its autologous natural killer cell treatment agent is effective in killing SARS-CoV-2.

Celularity begins trial of COVID-19 cell therapy
Celularity has received funding to support a phase I/II clinical trial of human placental hematopoietic stem cell-derived natural killer cells for the...